Sanofi's Brivekimig Shows Promise in Hidradenitis Suppurativa Treatment

Sanofi's brivekimig has achieved positive outcomes in a phase 2a study for treating hidradenitis suppurativa (HS). The study demonstrated significant improvements in patients who had not previously received biologic treatments. Brivekimig, a dual-target Nanobody® inhibiting TNF and OX40L, was tested in a double-blind, placebo-controlled trial. Results showed a 67% HiSCR50 response rate compared to 37% with placebo at week 16. Secondary endpoints, including HiSCR75 and HiSCR90, also favored brivekimig. Despite the investigational status of brivekimig, Sanofi is committed to exploring its impact on inflammation and HS symptoms further. The study's findings will be presented at the EADV 2025 Congress in Paris.